Skip to main content

Advertisement

SpringerLink
Log in

Is myeloperoxidase a useful marker to predict the risk of cardiovascular events?

  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Low-grade inflammation and oxidative stress have additional and potentially synergistic effects on the development of cardiovascular disease. Myeloperoxidase (MPO) concentration and activity are elevated in patients with low-grade inflammation and contribute to oxidative processes in the bloodstream. MPO and its by-products have been shown to adversely affect the protective capacity of high-density lipoprotein as well as endothelial function, thereby contributing to atherosclerosis, vascular inflammation, and plaque vulnerability. We describe the evidence supporting a role for MPO as a marker of plaque instability. We also summarize and discuss the evidence for an association between MPO levels and the risk of future cardiovascular risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Navab M, Ananthramaiah GM, Reddy ST, et al.: The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004, 45:993–1007.

    Article  PubMed  CAS  Google Scholar 

  2. Madamanchi NR, Vendrov A, Runge MS: Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005, 25:29–38.

    Article  PubMed  CAS  Google Scholar 

  3. Tsimikas S: In vivo markers of oxidative stress and therapeutic interventions. Am J Cardiol 2008, 101:34D–42D.

    Article  PubMed  CAS  Google Scholar 

  4. Genest J: The Yin and Yang of high-density lipoprotein cholesterol. J Am Coll Cardiol 2008, 51:643–644.

    Article  PubMed  Google Scholar 

  5. Maki-Petaja KM, Cheriyan J, Booth AD, et al.: Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction. Int J Cardiol 2008 Jun 18 (Epub ahead of print).

  6. Heinecke JW: The role of myeloperoxidase in HDL oxidation and atherogenesis. Curr Atheroscler Rep 2007, 9:249–251.

    Article  PubMed  CAS  Google Scholar 

  7. Mohiuddin I, Chai H, Lin PH, et al.: Nitrotyrosine and chlorotyrosine: clinical significance and biological functions in the vascular system. J Surg Res 2006, 133:143–149.

    Article  PubMed  CAS  Google Scholar 

  8. Link JJ, Rohatgi A, de Lemos JA: HDL cholesterol: physiology, pathophysiology, and management. Curr Probl Cardiol 2007, 32:268–314.

    Article  PubMed  Google Scholar 

  9. Joyce CW, Amar MJ, Lambert G, et al.: The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci U S A 2002, 99:407–412.

    Article  PubMed  CAS  Google Scholar 

  10. Sirtori CR, Calabresi L, Franceschini G, et al.: Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001, 103:1949–1954.

    PubMed  CAS  Google Scholar 

  11. Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292–2300.

    Article  PubMed  CAS  Google Scholar 

  12. Kontush A, Chapman MJ: Antiatherogenic small, dense HDL—guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006, 3:144–153.

    Article  PubMed  CAS  Google Scholar 

  13. van der Poll T, Braxton CC, Coyle SM, et al.: Effect of hypertriglyceridemia on endotoxin responsiveness in humans. Infect Immun 1995, 63:3396–3400.

    PubMed  Google Scholar 

  14. Zhang B, Bai H, Liu R, et al.: Serum high-density lipoprotein-cholesterol levels modify the association between plasma levels of oxidatively modified low-density lipoprotein and coronary artery disease in men. Metabolism 2004, 53:423–429.

    Article  PubMed  CAS  Google Scholar 

  15. Perségol L, Verges B, Gambert P, et al.: Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation. J Lipid Res 2007, 48:1396–1401.

    Article  PubMed  Google Scholar 

  16. Perségol L, Foissac M, Lagrost L, et al.: HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 2007, 50:2384–2387.

    Article  PubMed  Google Scholar 

  17. Bergt C, Pennathur S, Fu X, et al.: The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004, 101:13032–13037.

    Article  PubMed  CAS  Google Scholar 

  18. Zheng L, Nukuna B, Brennan ML, et al.: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004, 114:529–541.

    PubMed  CAS  Google Scholar 

  19. Pennathur S, Bergt C, Shao B, et al.: Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 2004, 279:42977–42983.

    Article  PubMed  CAS  Google Scholar 

  20. Marsche G, Hammer A, Oskolkova O, et al.: Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J Biol Chem 2002, 277:32172–32179.

    Article  PubMed  CAS  Google Scholar 

  21. Daugherty A, Dunn JL, Rateri DL, et al.: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994, 94:437–444.

    Article  PubMed  CAS  Google Scholar 

  22. Sugiyama S, Okada Y, Sukhova GK, et al.: Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001, 158:879–891.

    PubMed  CAS  Google Scholar 

  23. Hazen SL, Heinecke JW: 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997, 99:2075–2081.

    Article  PubMed  CAS  Google Scholar 

  24. Morton LW, Puddey IB, Croft KD: Comparison of nitration and oxidation of tyrosine in advanced human carotid plaque proteins. Biochem J 2003, 370:339–344.

    Article  PubMed  CAS  Google Scholar 

  25. Wang Z, Nicholls SJ, Rodriguez ER, et al.: Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007, 13:1176–1184.

    Article  PubMed  CAS  Google Scholar 

  26. Hazen SL, Zhang R, Shen Z, et al.: Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation in vivo. Circ Res 1999, 85:950–958.

    PubMed  CAS  Google Scholar 

  27. Kumar AP, Reynolds WF: Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 2005, 331:442–451.

    Article  PubMed  CAS  Google Scholar 

  28. Zhou T, Zhou SH, Qi SS, et al.: The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta 2006, 368:168–172.

    Article  PubMed  CAS  Google Scholar 

  29. Shishehbor MH, Aviles RJ, Brennan ML, et al.: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003, 289:1675–1680.

    Article  PubMed  CAS  Google Scholar 

  30. Davey Smith G, Ebrahim S: ’Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003, 32:1–22.

    Article  PubMed  Google Scholar 

  31. Piedrafita FJ, Molander RB, Vansant G, et al.: An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996, 271:14412–14420.

    Article  PubMed  CAS  Google Scholar 

  32. Nikpoor B, Turecki G, Fournier C, et al.: A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001, 142:336–339.

    Article  PubMed  CAS  Google Scholar 

  33. Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al.: A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int 2003:S172–S176.

  34. Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, et al.: Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med 2004, 116:429–430.

    Article  PubMed  CAS  Google Scholar 

  35. Makela R, Loimaala A, Nenonen A, et al.: The association of myeloperoxidase promoter polymorphism with carotid atherosclerosis is abolished in patients with type 2 diabetes. Clin Biochem 2008, 41:532–537.

    Article  PubMed  Google Scholar 

  36. Kutter D, Devaquet P, Vanderstocken G, et al.: Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol 2000, 104:10–15.

    Article  PubMed  CAS  Google Scholar 

  37. Zhang R, Brennan ML, Fu X, et al.: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286:2136–2142.

    Article  PubMed  CAS  Google Scholar 

  38. Kubala L, Lu G, Baldus S, et al.: Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clin Chim Acta 2008, 394:59–62.

    Article  PubMed  CAS  Google Scholar 

  39. Vita JA, Brennan ML, Gokce N, et al.: Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004, 110:1134–1139.

    Article  PubMed  CAS  Google Scholar 

  40. Exner M, Minar E, Mlekusch W, et al.: Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol. J Am Coll Cardiol 2006, 47:2212–2218.

    Article  PubMed  CAS  Google Scholar 

  41. Ndrepepa G, Braun S, Mehilli J, et al.: Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest 2008, 38:90–96.

    PubMed  CAS  Google Scholar 

  42. Meuwese MC, Trip MD, van Wissen S, et al.: Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia. Atherosclerosis 2008, 197:916–921.

    Article  PubMed  CAS  Google Scholar 

  43. Meuwese MC, Stroes ES, Hazen SL, et al.: Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007, 50:159–165.

    Article  PubMed  CAS  Google Scholar 

  44. Brennan ML, Penn MS, Van Lente F, et al.: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595–1604.

    Article  PubMed  CAS  Google Scholar 

  45. Cavusoglu E, Ruwende C, Eng C, et al.: Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007, 99:1364–1368.

    Article  PubMed  CAS  Google Scholar 

  46. Stefanescu A, Braun S, Ndrepepa G, et al.: Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J 2008, 155:356–360.

    Article  PubMed  CAS  Google Scholar 

  47. Mocatta TJ, Pilbrow AP, Cameron VA, et al.: Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007, 49:1993–2000.

    Article  PubMed  CAS  Google Scholar 

  48. Baldus S, Heeschen C, Meinertz T, et al.: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108:1440–1445.

    Article  PubMed  CAS  Google Scholar 

  49. Khan SQ, Kelly D, Quinn P, et al.: Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart 2007, 93:826–831.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Academic Medical Center, PO Box 22660, 1100 DD, Amsterdam, the Netherlands

    S. Matthijs Boekholdt

Authors
  1. Benoit J. Arsenault
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erik S. G. Stroes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Matthijs Boekholdt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Matthijs Boekholdt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arsenault, B.J., Stroes, E.S.G. & Boekholdt, S.M. Is myeloperoxidase a useful marker to predict the risk of cardiovascular events?. Curr Cardio Risk Rep 3, 137–143 (2009). https://doi.org/10.1007/s12170-009-0022-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12170-009-0022-y

Keywords

Search

Navigation